10-K: Protagonist Therapeutics Reports Positive Phase 3 Results and Significant Financial Gains in 2024

Protagonist Therapeutics highlights positive Phase 3 results for Icotrokinra, a worldwide license and collaboration agreement for Rusfertide with Takeda, and a strong cash position at the end of 2024.

Summary

• Protagonist Therapeutics is a biopharmaceutical company focused on peptide therapeutics, with clinical programs in hematology, blood disorders, and inflammatory and immunomodulatory diseases.
• Key highlights for 2024 include a worldwide license and collaboration agreement with Takeda for rusfertide, positive Phase 3 topline results from ICONIC studies of icotrokinra in plaque psoriasis, and the nomination of PN-881 as a potential best-in-class oral peptide IL-17 antagonist development candidate.
• The company ended fiscal year 2024 with approximately $559.2 million in cash, cash equivalents, and marketable securities, a significant increase from $341.6 million at the end of 2023.
• Rusfertide is in Phase 3 development for polycythemia vera (PV), with topline data expected in March 2025 and a potential NDA filing in the fourth quarter of 2025.
• Icotrokinra, licensed to J&J Innovative Medicines, showed significant skin clearance in Phase 3 trials for plaque psoriasis, with comprehensive results expected to be presented at upcoming medical congresses.
• The company nominated PN-881, an oral peptide IL-17 antagonist, as a development candidate, with a Phase 1 study expected to begin in the fourth quarter of 2025.
• Under the Takeda agreement, Protagonist received an upfront payment of $300 million and is eligible for up to $330 million in milestones, plus profit sharing in the U.S. and royalties outside the U.S..
• The J&J agreement was amended, increasing the milestone payment for a Phase 3 clinical trial meeting its primary endpoint to $165 million, and eliminating certain other milestone payments.
• Protagonist expects to nominate an oral development candidate in the hepcidin mechanism-based hematology program in the fourth quarter of 2025, and an oral peptide-based development candidate in the metabolic/obesity program in the second quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to successful clinical trial results, a major collaboration agreement, and a strong financial position. While risks are acknowledged, the overall tone is optimistic.

Positives

• The Takeda collaboration provides significant upfront funding and potential future revenue through milestones and royalties.
• Positive Phase 3 results for icotrokinra validate the company's peptide technology platform and its effectiveness in creating differentiated new chemical entities.
• The nomination of PN-881 as a development candidate expands the company's pipeline and addresses a clinically validated target.
• The company's strong cash position provides financial flexibility to advance its clinical programs and pursue new opportunities.
• Final results from the REVIVE trial presented at the American Society of Hematology (ASH) 2024 Annual Meeting in December 2024 showed that 54% of patients with PV experienced more than 2.5 years of durable hematocrit control (<45%), decreased phlebotomy use, long-term tolerability and improvements in patient-reported outcomes.

Risks

• The company has no approved products and no historical commercial revenue, making it difficult to assess future prospects and financial results.
• The company is heavily dependent on the success of its product candidates in clinical development, and failure can occur at any stage.
• Clinical development is a lengthy and expensive process with an uncertain outcome.
• Product candidates may cause undesirable side effects or have other properties adversely impacting safety.
• The company has incurred a cumulative net loss since its inception and anticipates that it may incur significant losses in the future.
• The company may require additional funding, which may not be available on acceptable terms, or at all.
• The company relies on J&J and Takeda to continue the development and commercialization of product candidates subject to collaboration agreements.
• The company relies on third parties to conduct pre-clinical studies and clinical trials and are subject to risks associated with their businesses and performance of their obligations.
• The company relies on third-party contract manufacturers to manufacture drug substance and clinical drug product.
• The company may be involved in lawsuits to protect or enforce intellectual property, which could be expensive, time consuming and ultimately unsuccessful.
• The company's stock price has been and will likely continue to be volatile and may decline, regardless of operating performance.

Future Outlook

The company expects to announce topline data for the VERIFY trial in March 2025, potentially leading to an NDA filing in the fourth quarter of 2025. Topline results for the ANTHEM trial are expected in the first quarter of 2025. Topline results for the ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and pustular/erythrodermic psoriasis trials are expected in the second quarter of 2025. The company expects to nominate an oral development candidate in the hepcidin mechanism-based hematology program in the fourth quarter of 2025, and an oral peptide-based development candidate in the metabolic/obesity program in the second quarter of 2025.

Management Comments

• JNJ highlighted icotrokinra as a potential firstand best-in-class targeted oral IL-23 peptide antagonist with potential across multiple indications, including plaque psoriasis, PsA and inflammatory bowel disease, with potential peak year sales projected at greater than $5.0 billion.
• We believe these positive Phase 3 results confirm the efficacy and safety trends that were observed with the previous Phase 2 FRONTIER 1 and 2 studies, highlighting icotrokinras potential as a best-in-class oral agent providing a combination of significant skin clearance with demonstrated tolerability in a once-daily pill for treating plaque psoriasis.
• We believe these results also continue to validate our innovative peptide technology platform and its effectiveness in creating highly differentiated new chemical entities to address unmet needs in various disease areas.

Industry Context

The document provides context on the competitive landscape in the biotechnology and pharmaceutical industries, specifically highlighting competition in the areas of PV, psoriasis, PsA, HS, axSpA, and IBD. It mentions competing products and companies, including Jakafi, Besremi, Cosentyx, Taltz, Tremfya, Skyrizi, Otezla, Xeljanz, Rinvoq, Entyvio, Stelara, Skyrizi, Omvoh, and others. The document also discusses the increasing emphasis on cost-containment initiatives and the potential impact on pricing and reimbursement for pharmaceutical products.

Comparison to Industry Standards

• The document mentions several competing drugs and their market performance, providing a benchmark for Protagonist's product candidates.
• For example, Stelara generated $10.4 billion in sales in 2024, and Tremfya generated $3.7 billion in sales in 2024.
• The document also notes that only 25% of biologic eligible moderate-to-severe psoriasis patients are treated with a biologic, indicating a significant unmet need.
• The document compares PN-881's potency to secukinumab and other approved antibody drugs and nanobody therapeutics in development.

Stakeholder Impact

• Shareholders: Positive results and financial stability may increase shareholder value.
• Employees: Company growth and success may lead to job security and career opportunities.
• Patients: Successful development of new therapies may provide improved treatment options.
• Suppliers: Increased demand for clinical trial materials and manufacturing services.
• Creditors: Strong financial position reduces credit risk.

Next Steps

• Announce topline data for the VERIFY trial in March 2025.
• Potential NDA filing for rusfertide in the fourth quarter of 2025.
• Present comprehensive results from ICONIC-LEAD and ICONIC-TOTAL at upcoming medical congresses.
• Share ICONIC-LEAD and ICONIC-TOTAL results with health authorities in planned submissions.
• Expect topline results for the ANTHEM trial in the first quarter of 2025.
• Expect topline results for the ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and pustular/erythrodermic psoriasis trials in the second quarter of 2025.
• Initiate a PN-881 Phase 1 study in the fourth quarter of 2025.
• Expect to nominate an oral development candidate in the hepcidin mechanism-based hematology program in the fourth quarter of 2025.
• Expect to nominate an oral peptide-based development candidate in the metabolic/obesity program in the second quarter of 2025.

Key Dates